ClinicalTrials.gg
Not yet recruitingNCT07446764IHSUpdated Nov 17, 2026

Integrated Health Services (IHS): A Structural Intervention to Improve HIV/STI Screening and PrEP Navigation in Primary Care

An interventional study of Integrated HIV/STI Testing and PrEP Navigation Model in HIV and STDs, sponsored by My Brother's Keeper, Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by My Brother's Keeper, Inc. · Not applicable, Interventional, and Health services research

How we know

Updated Nov 17, 2026Start date movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
700
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 283 studies in Sexually Transmitted Diseases with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Sexually Transmitted Diseases · United States.

Planned enrollment
75th of 251
700 · median 400
Started
2027
with 3 others
No phase
190 of 283
24 open now
Primary completion
2028-04
later than 26 of 41 live
Registered
274th of 283
by date

Among the 283 studies in Sexually Transmitted Diseases with a site in United States, this one is the 75th largest by planned enrollment of the 251 interventional ones that give a count, is one of 4 that started in 2027, is one of 190 with no phase, reaches primary completion later than 26 of the 41 other live ones, and was the 274th registered.

Sexually Transmitted Diseases

525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.

Browse Sexually Transmitted Diseases studies →

Open to participants now

32 of the 283 studies in Sexually Transmitted Diseases with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Sexually Transmitted Diseases with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether integrating routine, opt-out HIV and STI testing and pre-exposure prophylaxis (PrEP) navigation into primary care increases use of these services among adults ages 18 to 45 receiving care at Federally Qualified Health Centers in Mississippi. The main questions it aims to answer are:

  1. Does the integrated model increase HIV and STI testing compared with standard care?
  2. Does the integrated model increase PrEP navigation activity for eligible patients?
  3. How do patients and clinic staff experience the integrated model in terms of satisfaction, comfort discussing sexual health, and feasibility in daily workflows?

Researchers will compare a standard-care period to a period when the integrated model is in place to see if the integrated model improves service use and patient experience.

Participants will:

  1. Receive usual primary care, with HIV/STI testing and PrEP discussions offered as a routine, opt-out part of care during the integrated period
  2. Be invited, if eligible, to complete a brief survey about their clinic experience
  3. For staff, be invited to take part in a short survey or interview about clinic workflows and the integrated model
Read the detailed description

This is a quasi-experimental, mixed-methods implementation study designed to evaluate an integrated sexual and reproductive health (SRH) model that embeds routine, opt-out HIV and sexually transmitted infection (STI) testing and pre-exposure prophylaxis (PrEP) navigation into primary care workflows at two Federally Qualified Health Centers (FQHCs) in Canton and Yazoo City, Mississippi. The study focuses on adults ages 18-45 receiving primary care at participating clinics, a population experiencing high HIV/STI burden and structural barriers to SRH services, including limited routine testing, low PrEP uptake, and fragmented referral pathways. The intervention is informed by the Comprehensive Theory of Integration and aims to normalize HIV/STI testing as part of routine care while strengthening PrEP navigation and care coordination within existing clinic infrastructure.

The intervention operates at the clinic and workflow level rather than at the level of individual randomization. During the standard-care period, HIV/STI testing and PrEP discussions occur based on provider discretion or patient request, supported by existing electronic health record (EHR) prompts. During the integrated-care period, the study implements standing orders for nurses and peer navigators to initiate HIV tests, guideline-aligned STI tests, and PrEP navigation for eligible patients; EHR prompts and templates that cue providers to offer testing and PrEP in an opt-out manner; embedded peer navigation and daily team huddles to support linkage and follow-up; and training and technical assistance to promote culturally responsive, stigma-informed care. These changes are designed to be feasible within typical FQHC staffing and technology constraints.

The study uses a 24-month pre-post design, with a 12-month standard-care phase followed by a 12-month integrated-care phase. Primary quantitative data will be derived from de-identified or limited EHR extracts containing variables such as age, sex, race/ethnicity, visit type, HIV/STI test ordering and completion, PrEP offers and navigation steps, and documented declinations. Additional quantitative data will be collected through brief patient surveys assessing visit experience, satisfaction, comfort discussing sexual health, perceptions of opt-out testing, and experiences with PrEP discussions and navigation. Qualitative data will be obtained via semi-structured key-informant interviews and surveys with medical providers, nurses/medical assistants, patient navigators and community health workers, and clinic administrators, as well as interviews with a subset of patients, to explore implementation processes, barriers and facilitators, perceived impact, and sustainability.

No experimental drugs or devices are used, and all HIV/STI testing and PrEP services adhere to current clinical guidelines as part of routine care. The research procedures consist of (1) implementing and monitoring the integrated workflow; (2) abstracting EHR data under an IRB-approved waiver of consent and, where applicable, HIPAA authorization; and (3) collecting survey and interview data from patients and staff under informed consent. The primary implementation outcome is change in HIV/STI test uptake among adults ages 18-45 between the standard-care and integrated-care periods. Secondary outcomes include changes in PrEP navigation activity, patient-reported satisfaction and comfort discussing sexual health, provider adoption and fidelity to integrated SRH workflows, and feasibility and acceptability of the intervention from staff and patient perspectives. Analytic plans include pre-post comparisons of service uptake and navigation metrics, as well as thematic analysis of qualitative data to identify contextual factors (e.g., staffing, workflow, stigma, policy environment) that influence successful integration and scalability of the model in high-need FQHC settings.

03

Conditions studied

  • HIV
  • STDs

Keywords

  • HIV/AIDS
  • Sexual transmitted diseases
  • STDs
  • STIs
  • PrEP
  • Healthcare
  • Integrated healthcare
  • Sexual Health
  • Reproductive Health
  • Practice Guidelines
  • Intervention
  • Health Care Availability
  • Structural Determinants
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ages 18 to 45 years.
  • Receiving primary care services at participating Federally Qualified Health Center (FQHC) clinics in Canton or Yazoo City, Mississippi.
  • Able to understand and read English (for participation in surveys and interviews).
  • For staff key informants: current clinical, administrative, or support role at a participating FQHC site with responsibilities related to primary care, /STI services, or care coordination.

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 years or older than 45 years.
  • Critically ill, psychiatrically unstable, or lacking capacity to provide for research participation.
  • Unable to understand English for consent and survey/interview procedures.
  • For staff key informants: unable or unwilling to provide informed consent for interviews or surveys.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
700 participants (estimated)

Study arms

  • No intervention
    Standard Care

    Usual care delivered before implementation of the Integrated Health Services (IHS) model. HIV/STI testing and PrEP navigation occur at provider discretion without standardized workflows or EHR prompts. This represents the 12-month pre-intervention period.

  • Experimental
    Integrated HIV/STI and PrEP Care

    Care delivered during the 12-month intervention period using the Integrated Health Services (IHS) model, which incorporates routine opt-out HIV/STI screening, standing orders, EHR prompts, and standardized PrEP navigation workflows

    Behavioral: Integrated HIV/STI Testing and PrEP Navigation Model

Interventions

  • BehavioralIntegrated HIV/STI Testing and PrEP Navigation Model

    Clinic-level implementation of an integrated sexual and reproductive health model that embeds routine, opt-out HIV and sexually transmitted infection (STI) testing and pre-exposure prophylaxis (PrEP) navigation into primary care at Federally Qualified Health Centers. The intervention includes: (1) standing orders for nurses and peer navigators to initiate HIV/STI testing and PrEP navigation for eligible adults ages 18-45; (2) enhanced electronic health record prompts and templates to support opt-out testing and documentation of offers, completions, and declinations; (3) embedded peer navigation and daily team huddles to coordinate linkage and follow-up; and (4) training and technical assistance for clinic staff on workflows, cultural responsiveness, and stigma-reduction related to sexual health and PrEP.

06

What researchers measure

Primary outcomes

  1. HIV Testing Uptake

    Proportion of primary care visits among adults ages 18-45 at participating FQHC clinics with an HIV test completed (numerator: visits with HIV test completed; denominator: eligible visits for adults 18-45), comparing the standard-care period to the integrated-care period using electronic health record data.

    Time frame: 12 months during standard-care period and 12 months during integrated-care period

Secondary outcomes

  1. STI Testing Uptake

    Proportion of primary care visits among adults ages 18-45 with at least one guideline-aligned STI test (e.g., chlamydia, gonorrhea, syphilis) completed, comparing the standard-care period to the integrated-care period using electronic health record data.

    Time frame: 12 months during standard-care period and 12 months during integrated-care period

  2. PrEP Navigation Activity

    Proportion of eligible adult patients ages 18-45 with a documented PrEP offer and/or navigation step (e.g., referral, navigation contact, PrEP prescription) during primary care visits, comparing standard-care and integrated-care periods using electronic health record data.

    Time frame: 12 months during standard-care period and 12 months during integrated-care period

  3. Patient Satisfaction With Integrated Care

    Mean composite score on the patient satisfaction survey completed by adults ages 18-45 after a primary care visit during the integrated care period.

    Time frame: Within 7 days of an index primary care visit during the integrated-care period

  4. Staff Feasibility Rating

    Mean feasibility rating score from staff surveys assessing feasibility of the integrated-care workflows.

    Time frame: At 6 and 12 months after initiation of the integrated-care period

  5. Staff Acceptability Rating

    Mean acceptability rating score from staff surveys evaluating the acceptability of integrated workflows, including perceived usefulness, appropriateness, and value among providers, nurses/medical assistants, navigators, and administrators.

    Time frame: Assessed at 6 months and 12 months after initiation of the integrated care period.

07

Study locations

1 site
  • My Brother's Keeper, Inc.
    Ridgeland, Mississippi 39157, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) that underlie the primary and secondary outcome results (selected EHR variables for adults ages 18-45 and de-identified patient and staff survey responses) will be shared. No direct identifiers or HIPAA-defined identifiers will be included, and small cells will be handled to reduce re-identification risk. IPD will be available within 12 months after publication of the main study findings and for at least 5 years thereafter. Data will be shared with qualified researchers who have a scientifically sound proposal, appropriate ethics/IRB approval, and a signed data use agreement with My Brother's Keeper, Inc. and partner clinics. Data will be provided via secure, encrypted transfer or a controlled-access repository.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: De-identified IPD and supporting documents will be available beginning within 12 months after publication of the primary study results in a peer-reviewed journal or submission of the main results to ClinicalTrials.gov, whichever occurs first. Data will remain available for at least 5 years after initial release, or longer if required by funder or institutional policies. Requests received after that period may be considered on a case-by-case basis depending on data retention and feasibility.

Access criteria: De-identified IPD will be shared with qualified researchers at academic, clinical, or public health institutions for analyses that are consistent with the original study aims (for example, secondary implementation, health services, or equity-focused analyses) or address clearly justified, related scientific questions. Requestors must submit a brief research proposal, analysis plan, and evidence of IRB/ethics approval or exemption. Requests will be reviewed by the Principal Investigator and designated study leadership at My Brother's Keeper, Inc. and collaborating institutions to assess scientific merit, feasibility, and consistency with participant privacy protections and data-use agreements. Approved requestors will sign a data-use agreement that prohibits any attempt at re-identification and limits data use to the approved project. Data will be provided via secure, encrypted transfer or a controlled-access data repository.

Data sharing details ↗ · www.mbk-inc.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for Apr 2028, 11 months later.

Of 173 non-industry interventional studies with no phase under Sexually Transmitted Diseases, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 47. This study's planned 11 months is below that.

Counting every sponsor, half of 183 studies reached it within 31 months; a quarter within 16 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start Feb 2027 → May 2027 and completion Jul 2028 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Mar 3, 2026
StartEst.
May 1, 2027was Feb 2027
Primary completionEst.
Apr 30, 2028
CompletionEst.
Aug 1, 2028was Jul 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 1, 2027→May 1, 2027
Nov 17, 2026
Study completion
Jul 31, 2028→Aug 1, 2028
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Start date Feb 1, 2027→May 1, 2027
    Study completion Jul 31, 2028→Aug 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07446764
Lead sponsor
My Brother's Keeper, Inc.
Collaborators
University of Southern Mississippi, University of Mississippi Medical Center
Responsible party
June Gipson (Principle Investigator, My Brother's Keeper, Inc.) — Principal investigator
First posted
Mar 3, 2026
Start date
May 1, 2027 (estimated)
Primary completion
Apr 30, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

June A Gipson, PhD
Contact
jgipson@mbk-inc.org
769-216-2455 ext. 101
Edna S Lampkin, Pharm D.
Contact
elampkin@mbk-inc.org
769-216-2455 ext. 216
June A Gipson, PhD
principal investigator · My Brother's Keeper, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion